Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Gains from Investment Securities (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Gains from Investment Securities for 6 consecutive years, with $102785.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 82.32% to $102785.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $102785.0, a 82.32% decrease, with the full-year FY2024 number at $38785.0, changed 0.0% from a year prior.
  • Gains from Investment Securities was $102785.0 for Q3 2025 at Ensysce Biosciences, up from $64000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $11.6 million in Q3 2021 to a low of $1600.0 in Q1 2021.
  • A 5-year average of $1.0 million and a median of $45392.5 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 98.85% in 2023, then skyrocketed 2109.14% in 2024.
  • Ensysce Biosciences' Gains from Investment Securities stood at $11.6 million in 2021, then crashed by 99.77% to $26334.0 in 2022, then surged by 47.28% to $38785.0 in 2023, then changed by 0.0% to $38785.0 in 2024, then soared by 165.01% to $102785.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Gains from Investment Securities are $102785.0 (Q3 2025), $64000.0 (Q2 2025), and $52000.0 (Q1 2025).